Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Anti-CD38 CAR NK-cells: an off-the shelf therapy for multiple myeloma

Michael O’Dwyer • 17 May 2019
Multiple Myeloma Antibodies NK-Cell Therapy

Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses how anti-CD38 CAR NK-cells could selectively target myeloma cells to minimize off-target toxicity. This video was recorded at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Michael O’Dwyer

3:31
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
Michael O’Dwyer • 30 Nov 2020
5:14
Current myeloma cellular therapy landscape and horizon scan
Michael O’Dwyer • 30 Nov 2020
2:01
Cellular therapy: NK-cells as a model
Michael O’Dwyer • 21 May 2020
5:14
NK-cell enhancement: TRAIL variant
Michael O’Dwyer • 18 May 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals